Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT02903420

A Clinical Trial of Transcatheter Aortic Valves in Dialysis Patients (Japan)

A single arm, prospective, open, non-randomized, Japanese multicenter trial to evaluate the safety and effectiveness of the Edwards SAPIEN 3 Transcatheter Heart Valve System (Model: 9600TFX) in the treatment of symptomatic severe aortic stenosis patients on chronic dialysis, who are determined by the heart team to be unable to undergo safe open surgical therapy and have the benefits of the study valve implantation. Following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

19 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Osaka University Hospital, Suita, Osaka, Japan

Loading trial locations.

About this study

1-year mortality after the study valve implantation will be compared to the performance goal based on the literature review of clinical outcomes for dialysis patients who underwent surgical aortic valve replacement. Data will be collected from all patients for up to five years following the index valve replacement procedure.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient is determined by the heart team to be unable to undergo open surgical therapy and have the benefits of the study valve implantation.
  • Patient has senile degenerative aortic valve stenosis
  • Patient has been on dialysis (hemodialysis or peritoneal dialysis) in stable condition for ≥ 3 months.
  • Patient has appropriate aortic valve annulus size measured by TEE or 3D-CT.

Exclusion criteria

  • Patient has evidence of an acute myocardial infarction (MI) within 30 days prior to the index procedure.
  • Patient has a congenital unicuspid or bicuspid aortic valve, or non-calcified aortic valve.
  • Patient has severe aortic valve regurgitation.
  • Patient has severe mitral valve regurgitation.
  • Patient has an experience of any therapeutic invasive cardiac procedures within 30 days prior to the index procedure. Implantation of a permanent pacemaker or balloon valvuloplasty for bridging to procedure after a qualifying echo are not considered exclusionary.
  • Patient with planned concomitant surgical or transcatheter ablation for atrial fibrillation.

Treatment and study plan

Transcatheter Aortic Valve Implantation (TAVI)

Device

Implantation of Edwards SAPIEN 3 Transcatheter Heart Valve (Model: 9600TFX) via transfemoral, transapical or transaortic approach.

Primary outcomes

  1. Mortality

    Time frame: 1 year

    Number of Deaths

Secondary outcomes

  1. Device Success

    Time frame: 30 days

    Number of patients with device success, defined as absence of procedural mortality, correct positioning of a study valve into the proper anatomical location, and intended performance of the study valve (no prosthesis-patient mismatch and mean aortic valve gradient < 20 mmHg or peak velocity < 3 m/s, and no moderate or severe prosthetic valve regurgitation).

  2. Hospitalization Length of Stay

    Time frame: 7 days

    Discharge is defined as an average for 7 days

Sponsors and collaborators

Lead sponsor

Edwards Lifesciences

Industry

Registry information

Official study title

A Clinical Trial for Transcatheter Aortic Valve Implantation in Chronic Dialysis Patients With Aortic Valve Stenosis

Important dates

Study start
2016
Primary completion
2019
Study completion
2026
First posted
Sep 16, 2016
Registry last updated
Sep 25, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.